Biocon inks collaboration pact with US-based firm

Clinigene International, a subsidiary of Biocon, and Pacific Biomarkers Inc (PBI) announce a collaborative agreement to address the specialty biomarker and high end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry, Biocon said in a statement.

Commenting on the development Biocon Director of Research Services Peter Bains said: "We are delighted that PBI has selected Clinigene as its partner in India and we look forward to supporting PBI in extending and expanding its specialist service offerings".

"This partnership with India provides us access to India, an emerging hub for drug development and contact research," Pacific Biomarkers CEO Ronald Helm said.

Clinigene is India-based clinical research organisation while PBI is a Seattle-based firm that provides biomarker and specialty efficacy testing services to the drug development industry.
Shares of Biocon were trading at Rs 266.15 in the late afternoon trade on the BSE, up 4.01 per cent from previous close.